Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2021

View Archived Issues

Gunagratinib safe and active in patients with advanced solid tumors

Stuart initiates patient enrollment in phase II study of ST-100 for dry eye disease

PRV-111 nanoengineered cisplatin patch shows promising safety and efficacy in patient with OSCC

Shanghai Ennova Biopharmaceutical patents new TRK inhibitors

Sunshine Lake Pharma presents new antimigraine drugs

Shijiazhuang Yiling Pharmaceutical identifies HIPK2 inhibitors

Albiero Pharma synthesizes new ASBT and/or NTCP inhibitors

Preliminary first-in-human data presented for BDC-1001 in HER2-expressing solid tumors

Ossianix patents TfR1-targeting antibodies for neurodegeneration

U.K.'s MHRA clears initiation of phase II trial of COVID-DROPS

Phase Ia/b data for APTO-253 in patients with relapsed/refractory AML or high-risk MDS

Preliminary phase I results for NEXI-002 in R/R MM reported at EHA

Novavax reports COVID-19 vaccine data against SARS-CoV-2 Beta variant

Preliminary assessment of [68Ga]NOTA-GUL for the diagnosis of prostate cancer

ImmVira completes first dosing in phase II trials of oncolytic virus product MVR-T3011

Dosing begins in phase I study of novel cystic fibrosis therapy ETD-001

Rohto initiates phase I/II study of UDI-001 in pediatric patients with cerebral palsy

New target identified for acetaminophen liver injury

Inceptor Bio uses seed funding to advance next-generation cell therapy platforms for cancer

Lilly opens phase II trial of LY-3437943 in type 2 diabetes

First-in-human study of Carna's CDC7 inhibitor AS-0141 begins dosing

FDA lifts partial clinical hold on phase II studies of ALX-148 in HNSCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...